Male Hypogonadism Annual Evaluation Checklist

Why a Structured Annual Evaluation Matters

Hypogonadism affects an estimated 2 to 6% of adult men, with prevalence rising sharply after age 40 [1]. Without systematic annual review, clinicians miss dose drift, polycythemia, and worsening cardiovascular risk factors that accumulate silently over months of therapy.

The 2018 Endocrine Society Clinical Practice Guideline states: "We recommend measuring testosterone levels after 3 to 6 months of treatment to ensure that testosterone levels are in the mid-normal range and to check for adverse effects" [2]. Annual evaluation extends that logic across the full treatment timeline.

What "Annual" Actually Means in Practice

Annual does not mean a single lab draw once every 365 days. For men on injectable testosterone (testosterone cypionate or enanthate), the annual review should include at least one trough and one mid-cycle measurement to characterize the full pharmacokinetic curve. For transdermal gels and patches, a single steady-state draw two hours after application is acceptable [2].

The Cost of Skipping Annual Reviews

A 2021 retrospective analysis of 3,484 men on long-term TRT found that 18.3% had hematocrit values above 50% at 12 months, yet fewer than half had been counseled about phlebotomy or dose reduction [3]. Polycythemia raises whole-blood viscosity and may increase thrombotic risk, making this the single most consequential omission in annual follow-up.

Step 1: Symptom Reassessment

Annual symptom scoring establishes whether therapy is achieving its stated goals and whether new complaints have emerged.

Use the Aging Males' Symptoms (AMS) scale or the Androgen Deficiency in the Aging Male (ADAM) questionnaire at every annual visit. Both tools are validated and freely available [4]. A total AMS score above 37 on therapy suggests inadequate symptom control and warrants dose or formulation review.

Domains to Document

Document responses in three domains:

• Sexual function. Libido, erectile function (use the IIEF-5 as a five-item supplement if ED is the chief complaint), and morning erections.
• Somatic symptoms. Energy, sleep quality, muscle strength, and body composition changes. Ask specifically whether the patient has noticed increased fat mass around the abdomen.
• Psychological symptoms. Depressed mood, irritability, and cognitive complaints. The PHQ-9 takes less than three minutes and gives a trackable numerical score.

Red Flags Requiring Immediate Escalation

New-onset chest pain, dyspnea on exertion, or a palpable breast lump requires same-day escalation regardless of where the patient is in the annual cycle. Gynecomastia that has progressed from baseline should trigger estradiol measurement and a breast surgery consult if needed [2].

Step 2: Core Laboratory Panel

The annual lab panel for a man on testosterone therapy is not identical to the diagnostic panel used before treatment. The emphasis shifts from confirming deficiency to confirming safety.

Draw the following on the morning of the annual visit, ideally fasted for at least 8 hours [2]:

| Test | Rationale | Action Threshold | |---|---|---| | Total testosterone (morning) | Confirm mid-range target | <400 or >700 ng/dL: adjust dose | | SHBG | Calculate free T when total is borderline | Low SHBG (<20 nmol/L) may indicate hepatic issue | | Estradiol (LC-MS/MS) | Screen for aromatization excess | >42.6 pg/mL with symptoms: consider aromatase inhibitor | | CBC with hematocrit | Detect erythrocytosis | Hematocrit >54%: hold therapy | | Comprehensive metabolic panel | Hepatic and renal function | ALT >3x ULN: suspend oral androgen if applicable | | Fasting glucose and HbA1c | Metabolic monitoring | HbA1c ≥6.5%: formal diabetes workup | | Lipid panel | Cardiovascular risk | LDL >190 mg/dL: lipid-lowering therapy discussion | | PSA (men ≥40) | Prostate safety | Increase >1.4 ng/mL in 12 months: urology referral | | LH and FSH | Confirm suppression on TRT; rule out recovery if off-cycle | Detectable LH on TRT may indicate non-adherence |

Testosterone Assay Quality

Not all testosterone assays are equivalent. The CDC Hormone Standardization (HoSt) program sets harmonized reference intervals, and the CDC-harmonized lower cutoff for hypogonadism is 264 ng/dL, slightly below the Endocrine Society's 300 ng/dL threshold [1]. Request a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay whenever total testosterone falls in the 200 to 400 ng/dL range, because immunoassays carry a coefficient of variation of 15 to 20% at low concentrations [2].

Interpreting Estradiol Results

Supraphysiologic estradiol (above roughly 42.6 pg/mL by LC-MS/MS) in a symptomatic man, meaning one with gynecomastia, fluid retention, or mood lability, may justify anastrozole 0.5 mg twice weekly, but routine estradiol suppression in asymptomatic men is not recommended by current guidelines [2]. Estradiol is essential for bone health and libido; aggressive suppression often worsens outcomes.

Step 3: Cardiovascular and Metabolic Review

The relationship between testosterone therapy and cardiovascular risk generated intense debate after the 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial was stopped early due to excess cardiovascular events in the TRT arm [5]. Subsequent data have been more reassuring.

The TRAVERSE trial (N=5,246, mean age 63.5 years) published in the New England Journal of Medicine in 2023 found that testosterone replacement in men with hypogonadism and pre-existing or high cardiovascular risk did not increase rates of major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [6]. However, TRAVERSE also showed a statistically significant increase in atrial fibrillation (3.5% vs. 2.4%, P<0.001) and pulmonary embolism (0.9% vs. 0.5%, P=0.03) in the testosterone arm [6].

Annual cardiovascular review should therefore include:

• Blood pressure measurement (target <130/80 mmHg per AHA/ACC 2017 guidelines)
• Resting pulse rate and rhythm assessment with ECG if palpitations reported
• Fasting lipid panel with LDL-C as the primary target
• Body weight, waist circumference, and BMI
• Structured inquiry about symptoms of atrial fibrillation (palpitations, exertional fatigue)

Metabolic Syndrome Considerations

Testosterone deficiency is independently associated with insulin resistance and type 2 diabetes [7]. A meta-analysis of 20 randomized trials (N=1,822) published in the European Journal of Endocrinology found that testosterone therapy reduced fasting glucose by a mean of 0.64 mmol/L and HbA1c by 0.87% in men with type 2 diabetes [7]. Annual HbA1c and fasting glucose track both disease progression and one therapeutic benefit of TRT.

Step 4: Prostate Safety Monitoring

The Endocrine Society guideline recommends PSA measurement and digital rectal examination (DRE) at 3 to 6 months after initiating therapy and then annually in men aged 40 and older [2]. The threshold for urology referral is a PSA increase exceeding 1.4 ng/mL within any 12-month period or a PSA velocity above 0.4 ng/mL per year over two years [2].

What the Evidence Shows

A 2016 meta-analysis in the Journal of Urology covering 22 randomized controlled trials (N=2,351) found no statistically significant increase in PSA or prostate cancer incidence among men on TRT compared with placebo over follow-up periods ranging from 3 to 36 months [8]. This does not eliminate the need for monitoring, it informs the risk conversation with patients.

Men with a prior history of prostate cancer are not automatically excluded from testosterone therapy, but the decision requires shared decision-making with urology and documentation of at least 2 years of remission without biochemical recurrence [2].

DRE and Prostate Volume

Annual DRE remains part of the standard protocol for men aged 40 and older, despite its low sensitivity for early prostate cancer. A newly palpable nodule or induration warrants urology referral regardless of PSA value.

Step 5: Hematologic Safety, Polycythemia Protocol

Erythrocytosis is the most common laboratory adverse effect of testosterone therapy. Testosterone stimulates erythropoiesis through erythropoietin-dependent and erythropoietin-independent pathways [3]. The annual hematocrit draw is non-negotiable.

Thresholds and Actions

| Hematocrit | Action | |---|---| | <50% | Continue current regimen | | 50 to 54% | Increase monitoring to every 3 months; encourage hydration; consider dose reduction | | >54% | Hold testosterone; perform therapeutic phlebotomy; re-evaluate formulation |

Injectable testosterone (cypionate, enanthate) produces larger hematocrit swings than transdermal formulations or testosterone undecanoate (Aveed, Jatenzo) [2]. If a patient has persistent hematocrit of 50 to 52% on injections, switching to daily transdermal gel often stabilizes the hematocrit without sacrificing symptom control.

Venous Thromboembolism Risk

Polycythemia raises VTE risk, and testosterone therapy may independently increase VTE risk in predisposed individuals. TRAVERSE documented a pulmonary embolism rate of 0.9% in the TRT arm vs. 0.5% in placebo [6]. Annual visits should include a structured VTE risk screen using the Caprini score or a simple review of personal and family history.

Step 6: Bone Density and Musculoskeletal Review

Testosterone deficiency accelerates bone loss. Men with total testosterone below 200 ng/dL have a fracture risk roughly double that of eugonadal men [9].

DXA scanning should be performed:

• At baseline before starting TRT if any of the following are present: age above 50, prior fragility fracture, chronic glucocorticoid use, BMI <18.5, or total testosterone historically below 200 ng/dL.
• Every 1 to 2 years during therapy if the baseline T-score was below -1.5.
• Every 2 to 3 years if the baseline T-score was normal and the patient is asymptomatic.

A 12-month prospective study of 73 hypogonadal men starting testosterone gel showed lumbar spine BMD increased by a mean of 3.7% at 12 months and 5.9% at 24 months compared with baseline [9]. Annual DXA provides objective confirmation that therapy is achieving one of its key metabolic goals.

Step 7: Fertility Status and Gonadotropin Review

Testosterone therapy suppresses the hypothalamic-pituitary-gonadal (HPG) axis. LH and FSH fall to undetectable levels within 4 to 6 weeks of starting TRT, and sperm counts typically drop to azoospermic or severely oligospermic levels within 3 to 4 months [10].

At every annual visit, document the patient's current fertility intentions. If the patient wishes to preserve fertility or father children in the coming 12 months:

• Suspend exogenous testosterone.
• Start human chorionic gonadotropin (hCG) 500 to 2,000 IU subcutaneously three times weekly to maintain intratesticular testosterone and support spermatogenesis [10].
• Consider adding clomiphene citrate 25 mg every other day if LH recovery is slow.
• Refer to reproductive urology or a fertility specialist if semen analysis remains abnormal at 6 months.

Recovery Timeline

Spermatogenesis recovery after TRT cessation takes a median of 3 to 6 months but may take up to 24 months in men who were on therapy for more than 4 years [10]. Documenting pre-treatment semen analysis and banking sperm before starting TRT remains best practice for any man who has not completed his family.

Step 8: Formulation-Specific Considerations

Different testosterone delivery systems carry different monitoring priorities. The annual checklist must be adjusted by formulation.

Injectable Testosterone (Cypionate or Enanthate)

Peak-to-trough variation is the chief concern. Testosterone cypionate 100 mg IM weekly produces peak values of 700 to 900 ng/dL at 24 to 48 hours and troughs of 300 to 450 ng/dL at day 7 [2]. Annual review should include both a peak (24 to 48 h post-injection) and trough (immediately pre-injection) measurement if the patient reports symptom cycling, energy and libido crashing in the days before the next injection.

Transdermal Gels (AndroGel, Testim, Fortesta)

AndroGel 1% (testosterone gel) carries an FDA black-box warning about secondary exposure in women and children [11]. Annual review should include structured inquiry about application site hygiene and whether household contacts have shown signs of virilization.

Testosterone Undecanoate (Aveed, Jatenzo)

Aveed (injectable testosterone undecanoate 750 mg/3 mL) is administered at 0, 4, and then every 10 weeks. Because of the long dosing interval, the annual visit falls between injections; draw testosterone at the midpoint between doses (approximately 5 weeks post-injection) to get a representative steady-state level [11].

Jatenzo (oral testosterone undecanoate) requires twice-daily dosing with food. Annual review must include a fasting lipid panel because Jatenzo reduces HDL-C by a mean of 19%, more than any other approved testosterone formulation [11].

Step 9: Dose Optimization Framework

Annual evaluation is the primary opportunity to optimize dose based on 12 months of accumulated data. The following decision framework integrates symptom response, laboratory targets, and safety parameters:

Increase dose or frequency if:

• Total testosterone (mid-cycle) is consistently below 400 ng/dL
• AMS score has not improved by at least 10 points from baseline
• Hematocrit is below 48% (headroom exists for erythropoiesis)
• PSA is stable and DRE is unchanged

Decrease dose or switch formulation if:

• Hematocrit exceeds 52% on two consecutive draws
• Estradiol is above 42.6 pg/mL with symptomatic gynecomastia
• Total testosterone mid-cycle exceeds 700 ng/dL (supraphysiologic range)
• Patient reports peak-cycle side effects (acne, irritability, fluid retention) suggesting high peak-to-trough swing

Discontinue and reassess if:

• Hematocrit exceeds 54% and does not normalize after phlebotomy
• New prostate cancer diagnosis
• Untreated severe sleep apnea that worsens on TRT
• Patient develops symptomatic atrial fibrillation that cardiovascular team attributes to TRT

Step 10: Documentation Requirements

Every annual visit note should contain all of the following elements to meet medicolegal standards and to satisfy prior-authorization requirements for continued testosterone therapy:

1. Confirmed diagnosis with ICD-10 code (E29.1 for primary hypogonadism, E23.0 for secondary).
2. Two pre-treatment testosterone values (date, assay method, result) or documentation that these are on file from the initiating clinician.
3. Current formulation, dose, and frequency.
4. Symptom score (AMS or ADAM) with comparison to prior visit.
5. All laboratory results from the current annual panel with interpretive comment.
6. Hematocrit trend table covering all measurements since treatment initiation.
7. PSA trend table for men aged 40 and older.
8. DXA result or documentation of why DXA was deferred.
9. Fertility counseling note with patient's stated preferences.
10. Cardiovascular risk assessment with reference to ASCVD 10-year risk score.
11. Medication reconciliation including any aromatase inhibitors, hCG, or SARMs.
12. Plan for next follow-up and next lab draw with specific dates.